RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers

NCT ID: NCT02818972

Last Updated: 2025-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-10

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAU) of the descending thoracic aorta.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms and penetrating atherosclerotic ulcers of the descending thoracic aorta.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Aneurysm, Thoracic Penetrating Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RelayPro

Endovascular treatment with the investigational device.

Group Type EXPERIMENTAL

RelayPro

Intervention Type DEVICE

Endovascular treatment with investigational device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RelayPro

Endovascular treatment with investigational device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject must be ≥ 18 years of age
* Subject has specified disease in his/her descending thoracic aorta.
* Subject have anatomical compliance for the device specified for both access vessels and treatment area.
* Subject must be willing to comply with the follow-up evaluation schedule.
* Subject (or Legally Authorized Representative) agrees an Informed Consent Form prior to treatment.

Exclusion Criteria

* Subject has specified disease of the thoracic aorta which is not included in the trial, for example: aortic dissection, intramural hematoma, traumatic injury or transection, aortic false aneurysm, ruptured aneurysm.
* Subject anatomy with significant stenosis, calcification, thrombus or tortuosity.
* Subjects with specified compromised circulation.
* Subjects with specified prior procedures.
* Subjects with allergy to contrast media or device components.
* Subjects with disease, for example: suspected connective tissue disorder, specified coagulation disorders, specified coronary artery disease, severe congestive heart failure, stroke and/or Myocardial Infarction (MI) as specified, specified pulmonary disease, specified renal failure.
* Subjects that are pregnant or planning to become pregnant during the course of the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bolton Medical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wilson Szeto, MD

Role: PRINCIPAL_INVESTIGATOR

Penn Presbyterian

Venkatesh Ramaiah, MD

Role: PRINCIPAL_INVESTIGATOR

Arizona Heart Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama-Birmingham

Birmingham, Alabama, United States

Site Status

Arizona Heart Institute

Phoenix, Arizona, United States

Site Status

University of California, Irvine

Irvine, California, United States

Site Status

Long Beach Memorial Hospital

Long Beach, California, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

University of Florida

Gainesville, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Indiana University Health

Indianapolis, Indiana, United States

Site Status

St. Vincent Heart Center

Indianapolis, Indiana, United States

Site Status

University of Iowa Hospital and Clinic

Iowa City, Iowa, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Medical Center / Harvard Medical School

Boston, Massachusetts, United States

Site Status

Baystate Medical Center

Springfield, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Site Status

University Hospitals

Cleveland, Ohio, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

University of Pennsylvania Medical Center / Penn Presbyterian

Philadelphia, Pennsylvania, United States

Site Status

Lankenau Medical Center

Wynnewood, Pennsylvania, United States

Site Status

Centennial Heart & Vascular Institute Sarah Cannon Research Institute

Nashville, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

University of Texas Southwestern

Dallas, Texas, United States

Site Status

Baylor Scott & White Medical Center - Plano The Heart Hospital

Plano, Texas, United States

Site Status

Baylor Scot & White Medical Center - Temple

Temple, Texas, United States

Site Status

Nagoya University Hospital

Nagoya, Aichi-ken, Japan

Site Status

Hiroshima University Hospital

Hiroshima, Hiroshima, Japan

Site Status

Teine Keihinkai Hospital

Sapporo, Hokkaido, Japan

Site Status

Nara Medical University Hospital

Kashihara, Nara, Japan

Site Status

Niigata University Medical & Dental Hospital

Niigata, Niigata, Japan

Site Status

Oita University Hospital

Yufu, Oita Prefecture, Japan

Site Status

Morinomiya Hospital

Joto-ku, Osaka, Japan

Site Status

National Cerebral & Cardiovascular Center

Suita, Osaka, Japan

Site Status

Jichi Medical University Saitama Medical Center

Ōmiya, Saitama, Japan

Site Status

Jikei University Hospital

Minato-Ku, Tokyo, Japan

Site Status

Keio University Hospital

Shinjuku-Ku, Tokyo, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Japan

References

Explore related publications, articles, or registry entries linked to this study.

Szeto WY, Vallabhajosyula P, Matsuda H, Moainie SL, Sharafuddin MJ, Corvera J, Smolock CJ, Miyamoto S, Naslund T, Ramaiah V; RelayPro-A Investigators. One-year results with a low-profile endograft in subjects with thoracic aortic aneurysm and ulcer pathologies. J Thorac Cardiovasc Surg. 2022 May;163(5):1739-1750.e4. doi: 10.1016/j.jtcvs.2021.10.071. Epub 2022 Feb 1.

Reference Type DERIVED
PMID: 35241276 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IP-0015-16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.